The Digest’s 2026 Multi-Slide Guide to Dyadic International

Dyadic is pivoting from R&D to revenue generation with recombinant protein product launches slated for 2025–2027. Highlights include successful Phase 1 results for their DYAI-100 COVID-19 vaccine candidate and significant funding wins—a $4.5 million CEPI grant and $3 million from the Gates Foundation—to accelerate affordable vaccine and mAb production for global health. The company is now accepting orders for GMP-grade DNA/RNA enzymes and leveraging its C1 fungal platform to deliver high yields at lower costs.